SYNTHESIS OF [C-11] PLATELET-ACTIVATING-FACTOR (PAF) ANALOGS FOR IN-VIVO IMAGING OF PAF RECEPTORS

被引:2
作者
SASAKI, T
KARASAWA, K
ISHIWATA, K
SATOH, N
ISHII, S
OGAWA, K
NOZAKI, T
SETAKA, M
NOJIMA, S
SENDA, M
机构
[1] TEIKYO UNIV, FAC PHARMACEUT SCI, KANAGAWA 19901, JAPAN
[2] KITASATO UNIV, FAC HYG SCI, KANAGAWA 228, JAPAN
关键词
D O I
10.1002/jlcr.2580331006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
1-O-Hexadecyl-2-O-N,N-dimethylcarbamoyl-sn-glycero-3-phosphocholine[choline methyl-C-11] ([C-11]dimethylcarbamoyl-PAF) and 1-O-Hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine[choline methyl-C-11] ([C-11]C-16 -PAF) were synthesized as follows; Each of non-labeled dimethylcarbamoyl-PAF and C-16-PAF was treated with sodium benzene thiolate to derive their desmethyl-precursors containing a dimethylphosphoethanolamine at sn-3 . C-11-Labeled dimethylcarbamoyl-PAF and C16-PAF were synthesized by methylation of the respective desmethyl-precursors using ([C]CH3I)-C-11. The radiochemical yield of methylation in [C-11]dimethylcarbamoyl-PAF and [C-11]C-16-PAF was about 15 and 10 % (decay corrected), respectively. The lower yield of [C-11]C-16-PAF compared with that of [C-11]dimethylcarbamoyl-PAF was attributed to hydrolysis of the 2-acetyl group of [C-11]C-16-PAF during methylation. To study the stability to enzymatic hydrolysis, [C-11]dimethylcarbamoyl-PAF or [C-11]C-16-PAF was incubated with mouse plasma at 37-degrees-C. [C-11]Dimethylcarbamoyl-PAF remained intact for 60 min. On the other hand, almost all the radioactivity of [C-11]C-16-PAF was converted into [C-11]C-16-lyso-PAF in 5 min. These observations indicate that [C-11]dimethylcarbamoyl-PAF can be a suitable probe for in vivo imaging of PAF receptors.
引用
收藏
页码:921 / 931
页数:11
相关论文
共 12 条
[1]   PLATELET-ACTIVATING-FACTOR - A BIOLOGICALLY-ACTIVE PHOSPHOGLYCERIDE [J].
HANAHAN, DJ .
ANNUAL REVIEW OF BIOCHEMISTRY, 1986, 55 :483-509
[2]  
ISHIWATA K, 1993, IN PRESS APPL RAD IS
[3]   ANTIBODY TO PLATELET-ACTIVATING-FACTOR (1-O-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE - PAF) [J].
KARASAWA, K ;
FUJITA, K ;
SATOH, N ;
HONGO, T ;
SETAKA, M ;
OHNO, M ;
NOJIMA, S .
JOURNAL OF BIOCHEMISTRY, 1987, 102 (03) :451-453
[4]   RADIOIMMUNOASSAY FOR PLATELET-ACTIVATING-FACTOR [J].
KARASAWA, K ;
SATOH, N ;
HONGO, T ;
NAKAGAWA, Y ;
SETAKA, M ;
NOJIMA, S .
LIPIDS, 1991, 26 (12) :1126-1129
[5]   SPECIFIC BINDING OF ANTIBODIES TO PLATELET-ACTIVATING-FACTOR (PAF) AS DEMONSTRATED BY THIN-LAYER CHROMATOGRAPHY IMMUNOSTAINING [J].
KARASAWA, K ;
SATOH, N ;
HONGO, T ;
NAKAGAWA, Y ;
SETAKA, M ;
NOJIMA, S .
LIPIDS, 1991, 26 (12) :1122-1125
[6]   ANTIBODIES TO SYNTHETIC PLATELET-ACTIVATING-FACTOR (1-O-ALKYL-2-O-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE) ANALOGS WITH SUBSTITUENTS AT THE SN-2 POSITION [J].
KARASAWA, K ;
SATOH, N ;
MASUDA, M ;
SETAKA, M ;
HASHIMOTO, K ;
ISHIBASHI, K ;
NOJIMA, S .
JOURNAL OF BIOCHEMISTRY, 1991, 110 (05) :683-687
[7]   PLATELET-ACTIVATING-FACTOR IN STROKE AND BRAIN INJURY [J].
LINDSBERG, PJ ;
HALLENBECK, JM ;
FEUERSTEIN, G .
ANNALS OF NEUROLOGY, 1991, 30 (02) :117-129
[8]  
STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344
[9]  
STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215
[10]  
Stoffel W, 1975, Methods Enzymol, V35, P533